Biogen Idec Inc., the Weston biotechnology company known for its drugs to treat multiple sclerosis drugs, is seeking US regulatory approval for a long-lasting treatment for hemophilia A, a rare inherited disorder that impairs blood clotting.
Current treatments can require a patient to get three or four injections a week. Biogen Idec’s hope is that a patient would need one or two injections per week.
If approved, the treatment would be the first major advance for hemophilia A patients in more than two decades, the company said.
In a press release, the company said it is seeking Food and Drug Administration approval to the market recombinant factor VIII Fc fusion protein (rFVIIIFc) for the treatment of hemophilia A.
Chris Reidy can be reached at firstname.lastname@example.org.